Progress in studying induced pluripotent stem cell (iPSC) has been extremely rapid. Ever since the remarkable discovery of iPSCs by Takahashi and Yamanaka, the field has continued to evolve with exciting discoveries furthering our understanding of early development, the process of cellular reprogramming, acquisition and maintenance of pluripotency, determination of cell fate, and enhancing our ability to model diseases in vitro. These advances and the possibility of generating patient or disease specific pluripotent cells placed the field on a trajectory that may lead to personalized cell therapy in the near future.
Although there have been significant advances in iPSCbased research, significant challenges remain and these will need to be addressed before tangible outcomes can be realized. Such challenges include developing robust strategies to reprogram cells free of a viral/genetic foot print, resolving the immune and potential tumorigenicity issues, understanding better the genome and epigenome status of iPSC, and developing techniques to predict the quality of iPSC clones. Understanding the basic biology of iPSCs well enough to allow for successful transition of iPSCs into the clinic someday will also require additional studies.
To further discussion of the barriers in the field of iPSC biology, the guest editors of this special issue have compiled select original research findings and review articles describing important issues in iPSC research. These include manuscripts that describe the role of We are enthused to see the rapidity with which the field has advanced and how international in scope the field has become. It was gratifying for us to see papers from Asia, Europe, Australia, and America and it is perhaps appropriate given the title of the journal Stem Cells International.
We hope these latest review articles and original research articles in the field of iPSC research will promote and enable better understanding of the basic biology of iPSC that is critical for successful translation of iPSC for patient specific cell therapies in future.
